Emerald Mutual Fund Advisers Trust’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-104,825	Closed	-$11.2M	–	285
2023 Q1	$11.2M	Sell	104,825 -15,920	-13%	-$1.83M	0.66%	69
2022 Q4	$13.3M	Buy	+120,745	New	+$7.83M	0.82%	55

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's RXDX Position: Q2 2023 in Review

Emerald Mutual Fund Advisers Trust sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 104,825 shares — an estimated $11.2M sold.

Emerald Mutual Fund Advisers Trust first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $13.3M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Emerald Mutual Fund Advisers Trust reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Emerald Mutual Fund Advisers Trust sold 104,825 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $11.2M.
Emerald Mutual Fund Advisers Trust first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Emerald Mutual Fund Advisers Trust's Prometheus Biosciences, Inc. Common Stock position peaked at $13.3M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q2 2023, filed 10 Aug 2023.